Ascendis Pharma Earnings Call Transcripts
Fiscal Year 2026
-
YUVIWEL is set for a U.S. launch in early Q2 following FDA approval, targeting both untreated and switch patients with a differentiated weekly dosing profile and strong safety data. Pricing will reflect its clinical benefits, and international expansion is planned.
-
YUVIWEL received FDA approval as the first once-weekly therapy for children with achondroplasia, showing significant efficacy and safety in clinical trials. Commercial launch is planned for early Q2 2026, with label expansion and international rollout to follow.
-
2025 revenue reached $1.86B, with strong cash reserves and no major debt. Elevidys and PMOs drive growth, while next-gen siRNA pipeline advances. Focus in 2026 is on expanding Elevidys access, early intervention, and progressing key R&D milestones.
-
The phase 2 Coach trial in children with Achondroplasia showed that combining TransCon CNP and Growth Hormone led to unprecedented annualized growth velocities, significant improvements in body proportionality and arm span, and a strong safety profile. These results set a new efficacy benchmark and support advancing to phase 3 trials.
Fiscal Year 2025
-
Strong 2025 performance with EUR 720M revenue, led by YORVIPATH and SKYTROFA growth, supports a robust outlook for 2026. Pipeline advances, global launches, and a solid cash position underpin targets of EUR 500M operating cash flow in 2026 and EUR 5B annual revenue by 2030.
-
Q3 2025 saw strong revenue growth, positive operating profit, and robust global uptake for Yorvipath and SkyTrofa. Continued expansion, stable pricing, and new market launches are expected to drive further growth, with regulatory milestones for TransCon CNP on the horizon.
-
TransCon technology drives a robust pipeline with three key products targeting rare diseases and growth disorders. YORVIPATH’s launch is progressing with strong U.S. uptake and global expansion, while TransCon CNP offers unique clinical benefits. Financial independence and operational efficiency support continued growth.
-
Q2 2025 saw strong revenue growth, led by YORVIPATH's global launch and SKYTROFA's label expansion. The company expects to achieve cash flow positivity this year, with continued momentum from new approvals and robust uptake across key products.
-
The COACH phase 2 interim results show that combining TransCon CNP and Growth Hormone in children with achondroplasia led to unprecedented growth acceleration, with annualized growth velocities exceeding the 97th percentile for average-stature children and significant improvements in body proportionality, all with a favorable safety profile. A phase 3 trial is planned for later this year.
-
Yorvipath's US launch drove a major revenue increase and high patient uptake, while Skytrofa maintained strong market share and stable pricing. Substantial revenue growth is expected in 2025, with continued expansion and positive clinical progress across the portfolio.
-
Yorvipath's US launch targets a large, previously underserved patient pool, with rapid prescriber expansion and strong revenue growth. European rollout is progressing, with broader reimbursement expected by 2026. The pipeline includes a promising combo trial in achondroplasia.
-
The conference highlighted robust revenue growth, global expansion, and strong product uptake, especially for Skytrofa and Yorvipath. Strategic partnerships and pipeline innovation position the company for blockbuster status and potential cash flow break-even by year-end.
Fiscal Year 2024
-
Strong 2024 performance driven by Skytrofa and Yorvipath launches, with robust revenue growth, expanding market share, and a solid cash position. Yorvipath's U.S. launch shows high early demand, and further global expansion is underway. Continued pipeline progress and new collaborations support long-term growth.
-
SkyTrofa and YorviPath drove strong volume growth, with SkyTrofa up over 60% year-over-year and YorviPath preparing for a major U.S. launch. Financials remain robust, with EUR 626 million in cash and 2024 revenue guidance for SkyTrofa at EUR 200–220 million, excluding prior period deductions.
-
Top-line results from the APPROACH trial show TransCon CNP significantly increased annualized growth velocity and improved height Z-scores in children with achondroplasia, with a favorable safety profile and positive quality of life trends. Regulatory submissions are planned for 2025.
-
Yorvipath achieved strong US and EU launches with high retention, while Skytrofa volume doubled but Q2 revenue fell due to market access resets and true-ups. Full-year Skytrofa revenue is guided at €220–240M, with pivotal TransCon CNP data expected soon.
-
FDA approved Yorvipath as the first hormone replacement for adult hypoparathyroidism in the U.S., with a broad label and no REMS. Launch begins immediately, leveraging existing infrastructure, with robust efficacy and safety data supporting use.
-
Key pipeline products are advancing, with SKYTROFA surpassing 10,000 patients and YORVIPATH expanding across Europe. Regulatory milestones include an FDA PDUFA extension for TransCon PTH to August 2024, while pivotal data for TransCon CNP and oncology updates are expected by year-end.